Galpha 12 and Galpha 13 Stimulate Rho-dependent Tyrosine Phosphorylation of Focal Adhesion Kinase, Paxillin, and p130 Crk-associated Substrate*

Leila K. NeedhamDagger and Enrique Rozengurt§

From the Imperial Cancer Research Fund, London WC2A 3PX, United Kingdom

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

We examined whether constitutively active mutants of the Galpha proteins Galpha 12 and Galpha 13, which together comprise the G12 subfamily of Galpha proteins, induce Rho-dependent tyrosine phosphorylation of the focal adhesion proteins p125 focal adhesion kinase, paxillin, and p130 Crk-associated substrate. We report that transient expression of the constitutively active mutants of Galpha 12 or of Galpha 13 in human embryonic kidney 293 cells stimulates tyrosine phosphorylation of a set of proteins of Mr of 110,000-130,000, 97,000, and 60,000-70,000. We identified p125 focal adhesion kinase, paxillin, and p130 Crk-associated substrate as prominent tyrosine-phosphorylated proteins in human embryonic kidney 293 cells expressing constitutively active Galpha 12 and Galpha 13. In common with the increased tyrosine phosphorylation of these proteins mediated by mitogens acting through heptahelical receptors, the Galpha 12- and Galpha 13-mediated increase in tyrosine phosphorylation is blocked by cytochalasin D, which specifically disrupts the actin cytoskeleton, and by the Clostridium botulinum C3 exoenzyme, which ADP-ribosylates and inactivates Rho. Our results support the hypothesis that Galpha 12 and Galpha 13 activate Rho and suggest that Galpha 12 and Galpha 13 may mediate the tyrosine phosphorylation of p125 focal adhesion kinase, paxillin, and p130 Crk-associated substrate.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Many mitogens, including bioactive lipids such as lysophosphatidic acid (LPA)1 and neuropeptides such as bombesin, signal through distinct cell surface proteins that are members of the superfamily of G-protein-coupled receptors (GPCRs) with seven putative transmembrane domains. In Swiss 3T3 cells, a useful model system to analyze the mechanisms of growth factor signaling, an early event in the signal transduction pathways activated by these mitogens is the tyrosine phosphorylation of a common set of focal adhesion proteins (1). Treatment of Swiss 3T3 cells with GPCR agonists including bioactive lipids (2-4) and mitogenic neuropeptides such as bombesin (5-7) stimulates tyrosine phosphorylation of proteins with apparent Mr of 110,000-130,000, 97,000, and 60,000-70,000 on SDS-polyacrylamide gels. The nonreceptor tyrosine kinase p125fak (8, 9) and the adaptor proteins paxillin (10, 11) and p130cas (12), which localize to focal adhesion plaques, have been identified as prominent tyrosine-phosphorylated proteins in agonist-stimulated Swiss 3T3 cells (3, 4, 13-20). The increases in tyrosine phosphorylation of p125fak, paxillin, and p130cas are accompanied by profound alterations in the organization of the actin cytoskeleton in Swiss 3T3 cells, leading to the formation of actin stress fibers and the assembly of focal adhesions (3, 4, 21, 22). RhoA, a member of the Ras superfamily of low molecular weight GTPases, has been shown to direct stress fiber formation and focal adhesion assembly in Swiss 3T3 cells (23, 24). We proposed that the tyrosine phosphorylation of p125fak, paxillin, and p130cas mediated by heterotrimeric G-proteins is downstream of RhoA activation and focal adhesion assembly (1, 25-28). Signaling through p125fak, paxillin, and p130cas has been implicated in the regulation of cell migration, proliferation, and transformation (20, 29-32).

The immediate mechanism(s) coupling mitogen-induced activation of GPCRs to tyrosine phosphorylation of focal adhesion proteins is not understood. Although many GPCRs couple to the pertussis toxin-sensitive Gi, Gi does not appear to mediate increases in protein tyrosine phosphorylation (1, 33). Galpha 12 and Galpha 13, which together comprise the ubiquitously expressed G12 subfamily of Galpha proteins, are distantly related to other G-protein alpha  subunits and are pertussis toxin-insensitive (34, 35). There is increasing evidence indicating that Galpha 12 and Galpha 13 are involved in cell migration, proliferation, and transformation. Expression of mutationally activated Galpha 12 stimulates cellular entry into DNA synthesis, proliferation, and malignant transformation in NIH3T3 and Rat-1 cell lines (36-41) and promotes stress fiber formation and focal adhesion assembly in Swiss 3T3 cells (42). Furthermore, in astrocytoma cells, thrombin-induced stimulation of DNA synthesis was prevented by the microinjection of anti-Galpha 12 antibody (43). Gene disruption experiments have implicated Galpha 13 in the regulation of cell migration (44). The downstream targets through which Galpha 12 and Galpha 13 induce these effects have not been identified, although Ras-, Rac-, Rho-, and Cdc42-dependent pathways leading to cytoskeletal reorganization and to the activation of mitogen-activated protein kinase, Jun N-terminal kinase, and the Na+-H+ exchanger have been implicated (40, 45-48). However, it is not known whether activation of Galpha 12 and/or Galpha 13 can also promote the tyrosine phosphorylation of the nonreceptor protein tyrosine kinase p125fak and the adaptor proteins paxillin and p130cas.

To examine whether the G12 subfamily of heterotrimeric G-proteins induce protein tyrosine phosphorylation, we have transiently transfected human embryonic kidney HEK 293 cells with expression vectors encoding constitutively active Galpha 12 and Galpha 13 proteins and determined the effect of the expression of these activated Galpha subunits on the tyrosine phosphorylation of p125fak, paxillin, and p130cas. Our results demonstrate that expression of active Galpha 12 and Galpha 13 in HEK 293 cells induces tyrosine phosphorylation of these focal adhesion proteins through a pathway that requires the integrity of the actin cytoskeleton and functional Rho.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

cDNA Constructs-- The murine Galpha 12 subunit cDNAs in the eucaryotic expression vector pcDNA-1 (Invitrogen) were gifts from Dr. H. R. Bourne (University of California at San Francisco, CA) and included the constitutively active mutants Galpha 12-Q229L and Galpha 13-Q226L (Galpha 12QL and Galpha 13QL) (37). The constitutively active mutant murine Galpha i-2-Q205L (Galpha i-2QL) and Galpha q-Q209L (Galpha qQL) subunit cDNAs in pcDNA-1 (49, 50) were obtained from the American Type Tissue Collection (Manassas, VA). The Clostridium botulinum C3 exoenzyme (C3 toxin) cDNA in the eucaryotic expression vector EFplink, EFC3, was a gift from Dr. R. Treisman (Imperial Cancer Research Fund, London, UK). This construct encodes the C3 toxin under the control of the human polypeptide chain elongation factor 1alpha (EF-1alpha ) promoter (51).

Cell Culture and Transfection-- Cultures of transformed HEK 293 cells were maintained in DMEM supplemented with 10% fetal bovine serum in a humidified atmosphere containing 10% CO2 at 37 °C. HEK 293 cells were transfected with the various plasmids by calcium phosphate precipitation (52) or with LipofectAMINETM (Life Technologies, Inc.). The conditions for transient transfection of HEK 293 cells using calcium phosphate precipitation and LipofectAMINE were each optimized to yield peak efficiency of transfection using an expression plasmid encoding beta -galactosidase under the control of the human polypeptide chain elongation factor 1alpha (EF-1alpha ) promoter (pEFlacZ, a gift from R. Treisman). Both transfection methods yielded greater than a 50% transfection efficiency optimally, and we were unable to match this transfection efficiency with Lipofectin or DEAE-dextran-mediated transfection methods. Briefly, HEK 293 cells were plated at a density of 1.2 × 106 cells/60-mm Nunc dish and transfected the following day. For calcium phosphate transfections, 12.5 µg of plasmid DNA (precipitated in 0.25 ml of 140 mM NaCl, 0.75 mM Na2HPO4, 125 mM CaCl2, 20 mM PIPES, pH 6.95) was added per dish containing 2.25 ml of Optimem-1 medium, and the dishes were incubated for 4 h at 5% CO2. For LipofectAMINE transfections, HEK 293 cells were transfected with 3 µg of plasmid DNA and 25 µl of LipofectAMINE in 3 ml of Optimem-1/dish for 18 h at 5% CO2 according to the manufacturer's specifications. In the cotransfection experiments, total amounts of DNA were kept constant, and equal amounts of Galpha and of C3 expression constructs (or vector without cDNA insert) were mixed. After transfection with calcium phosphate or LipofectAMINE, the cells were washed and maintained in DMEM supplemented with 10% fetal bovine serum. All cultures were used for experimental purposes 4 days after plating.

Immunoprecipitation-- Cultures (one 60-mm dish/condition) were washed twice with DMEM and equilibrated in 5 ml of the same medium at 37 °C for 1-2 h. Some dishes were treated with inhibitors during this equilibration period or with growth factors for 10 min at the end of this period as indicated. Cultures were lysed in 1.4 ml of ice-cold lysis buffer A (10 mM Tris-HCl, pH 7.6, 5 mM EDTA, 50 mM NaCl, 30 mM sodium pyrophosphate, 50 mM NaF, 1% Triton X-100) supplemented with 2 mM Na3VO4, 1 mM 4-(aminoethyl)-benzenesulfonyl fluoride and 0.1% SDS. Lysates were clarified by centrifugation at 20,800 × g for 10 min at 4 °C. In some experiments, the cultures were washed and lysed as described above, with the exception that DMEM without phenol red was used, and the lysates were adjusted to 1 mg protein/ml after protein determination using the bicinchoninic acid protein assay (Pierce). 1 ml of the lysate was immunoprecipitated at 4 °C for 3-4 h with anti-mouse IgG-agarose-linked mAb directed against phosphotyrosine (4G10 or PY72), p125fak (2A7), paxillin, or p130cas or with Protein A-agarose-linked rabbit antisera directed against p125fak.

Western Blot Analysis-- Immunoprecipitates were washed three times by centrifugation with lysis buffer A supplemented with 1 mM Na3VO4 and extracted in 1× Laemmli sample buffer containing 1 mM EDTA for 10 min at 100 °C. The solubilized proteins were fractionated by discontinuous SDS-polyacrylamide gel electrophoresis (53) under reducing conditions on an 8% acrylamide resolving gel. Proteins were transferred onto polyvinylidene fluoride membranes (ImmobilonTM-P) at 4 °C for 2 h at 35 V and 2 h at 70 V in 48 mM Tris, 386 mM glycine, 0.1% SDS, and 20% methanol. The membranes were then blocked with 1% polyvinylpyrrolidone, 0.05% Tween 20, 0.02% sodium azide in phosphate-buffered saline, pH 7.4 (blocking buffer) (54) and incubated for 2 h with anti-phosphotyrosine (anti-Tyr(P)) mAb (4G10, 1 µg/ml) in blocking buffer. For some experiments, cultures were immunoprecipitated with anti-paxillin and with anti-p130cas mAb in duplicate, and parallel Western blots were probed with anti-Tyr(P) antibody and with the immunoprecipitating antibody to verify that equivalent amounts of protein were immunoprecipitated. Bound antibodies were visualized by the binding of 125I-labeled anti-mouse IgG (0.1 µCi/ml) followed by autoradiography. After autoradiographic detection of bound anti-Tyr(P), membranes from anti-p125fak immunoprecipitates were reprobed with rabbit antiserum directed against p125fak (1:500) and horseradish peroxidase-conjugated donkey antibodies to rabbit IgG (1:5,000). Immunoreactive p125fak was detected by enhanced chemiluminescence Western blotting ECLTM reagents (Amersham Pharmacia Biotech).

For analysis of Galpha subunit expression, identical samples of 50 µl (50 µg of protein) of the excess clarified lysate were diluted with 50 µl of 2× Laemmli sample buffer containing 2 mM EDTA and heated for 10 min at 100 °C. The proteins were fractionated by SDS-polyacrylamide gel electrophoresis on 10% acrylamide resolving gels. Proteins were transferred onto ImmobilonTM-P polyvinylidene fluoride membranes at 4 °C for 3 h at 400 mA in 25 mM Tris, 192 mM glycine, and 20% methanol. After blocking the membranes as above, immunoreactive Galpha subunits were visualized with rabbit antisera directed against Galpha 12, Galpha 13, Galpha i -1/Galpha i-2, or Galpha q at 1:500-1:1,000 dilution, 125I-labeled Protein A (0.1 µ Ci/ml), and autoradiography. The Galpha 13 antiserum was raised against the synthetic peptide CLHDNLKQLMLQ (which corresponds to the carboxyl-terminal peptide 367-377 of murine Galpha 13 with an N-terminal cysteine added for coupling) cross-linked to keyhole limpet hemocyanin with the heterobifunctional reagent sulfosuccinimidyl 4-(p-maleimidophenyl) butyrate as described by Offermanns et al. (55). The Galpha q antiserum was raised against a synthetic peptide (corresponding to amino acid residues 119-133 of murine Galpha q) cross-linked to keyhole limpet hemocyanin with glutaraldehyde.

Reproducibility-- Although both the calcium phosphate and the LipofectAMINE transfection methods appeared to yield little variation in levels of expression of Galpha proteins between dishes in a single transfection, both methods yielded variation in levels of expression of Galpha proteins between experiments. Although this variation in the levels of expression of the Galpha proteins was reflected in the variation in the levels of increased protein tyrosine phosphorylation, the reported experiments were repeated at least two times with results equivalent to those illustrated.

Materials-- LipofectAMINETM and Optimem-1 were obtained from Life Technologies, Inc., and the bicinchoninic acid BCA*TM protein assay reagent was obtained from Pierce. The anti-Tyr(P) mAb 4G10 and the anti-p125fak mAb 2A7 were obtained from Upstate Biotechnology, Inc.; mAbs directed against paxillin and p130cas were obtained from Transduction Laboratories; the rabbit anti-p125fak antiserum C-20 and rabbit anti-Galpha 12 were obtained from Santa Cruz Biotechnology, Inc.; and the rabbit anti-Galpha i-1/Galpha i-2 was obtained from Calbiochem. 125I-Labeled sheep anti-mouse IgG (100 µCi/ml), 125I-labeled protein A (100 µ Ci/ml), horseradish peroxidase-conjugated donkey anti-rabbit Ig, and the ECLTM Western blotting detection reagents were from Amersham International. Polyvinylidene fluoride ImmobilonTM-P Western blotting membranes were obtained from Millipore. Anti-mouse IgG-linked agarose, Na3VO4, thrombin, 1-oleoyl-LPA, phorbol 12,13-dibutyrate, epidermal growth factor, cytochalasin D, pertussis toxin, polyvinylpyrrolidone 40, and thapsigargin were obtained from Sigma. GF109203X and U73122 were obtained from LC Laboratories. The synthetic Galpha 13 peptide CLHDNLKQLMLQ was obtained from Research Genetics. The anti-Tyr(P) mAb PY72 was obtained from the Hybridoma Development Unit, Imperial Cancer Research Fund. All other reagents were of the highest available grade from standard commercial sources.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Thrombin-mediated Tyrosine Phosphorylation of Focal Adhesion Proteins in HEK 293 Cells-- Elements of the signal transduction pathways mediating the tyrosine phosphorylation of focal adhesion proteins downstream of GPCRs have been well characterized in Swiss 3T3 cells. We were interested in using a transient transfection system to analyze the ability of the G12 subfamily of heterotrimeric G-proteins to induce tyrosine phosphorylation of focal adhesion proteins. We elected to use HEK 293 cells for these studies because these cells can be efficiently transfected. However, signal transduction pathways exhibit a degree of heterogeneity in different cells types. Consequently, we initially examined tyrosine phosphorylation induced by ligands of GPCRs in HEK 293 cells.

As thrombin causes GPCR-mediated activation of Galpha 12 and Galpha 13 (43, 44, 55), we examined the effects of thrombin on tyrosine phosphorylation in HEK 293 cells. Lysates from these cells treated with or without thrombin were immunoprecipitated with anti-Tyr(P) mAb PY72 or mAbs directed against p125fak, paxillin, and p130cas. The immunoprecipitates were then subjected to Western blot analysis with the anti-Tyr(P) mAb 4G10. As illustrated by Fig. 1 (left panel), treatment of HEK 293 cells with thrombin resulted in increased tyrosine phosphorylation of proteins with apparent Mr of 110,000-130,000, 97,000, and 60,000-70,000. This pattern is identical to that elicited by GPCR agonists in Swiss 3T3 cells (3-6, 13, 14). Fig. 1 (right panels) shows that thrombin stimulated tyrosine phosphorylation of p125fak, paxillin, and p130cas in HEK 293 cells. p125fak and paxillin exhibit a greater increase in tyrosine phosphorylation in response to thrombin than does p130cas. Western blot analysis confirmed that similar amounts of p125fak, paxillin, and p130cas protein were immunoprecipitated (data not shown). Stimulation of HEK 293 cells with LPA resulted in an identical pattern of protein tyrosine phosphorylation and in increased tyrosine phosphorylation of p125fak, paxillin, and p130cas (data not shown).


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 1.   Thrombin induces tyrosine phosphorylation of p125fak, paxillin, and p130cas in HEK 293 cells. HEK 293 cells were washed and incubated for 1 h in DMEM before treatment for 10 min with 1 NIH unit of thrombin/ml (+) or solvent (-). Tyrosine phosphorylation was then analyzed by immunoprecipitation (IP) with anti-Tyr(P) mAb PY72 (PY), mAb 2A7 directed against p125fak (FAK), mAb directed against paxillin (PAX), or mAb directed against p130cas (CAS) and Western blotting (Blot) the immunoprecipitates with anti-Tyr(P) mAb 4G10 (PY). Molecular mass markers (in kDa) are indicated on the left.

Thrombin-induced Tyrosine Phosphorylation of p125fak, Paxillin, and p130cas Requires an Intact Cytoskeleton but Is Independent of PKC, Ca2+, and Pertussis Toxin-sensitive G-proteins-- Agonist-mediated tyrosine phosphorylation of focal adhesion proteins in Swiss 3T3 cells occurs through a PKC-, Ca2+-, and Gi-independent pathway that is critically dependent on the integrity of the actin cytoskeleton and of functional Rho (1, 3, 4, 14, 15, 25, 26). Direct PKC activation by phorbol esters can also lead to tyrosine phosphorylation of these proteins in Swiss 3T3 cells (14, 15, 20). As illustrated by Fig. 2 (upper left panel), the phorbol ester phorbol 12,13-dibutyrate also induced tyrosine phosphorylation of p125fak, paxillin, and p130cas in HEK 293 cells. The PKC inhibitor GF109203X (56, 57) prevented the tyrosine phosphorylation induced by phorbol 12,13-dibutyrate but did not inhibit the thrombin-induced tyrosine phosphorylation of p125fak, paxillin, or p130cas in HEK 293 cells, suggesting that PKC activation does not mediate agonist-induced tyrosine phosphorylation of focal adhesion proteins in HEK 293 cells. Similarly, treatment with pertussis toxin to inactivate Gi, thapsigargin to deplete the endoplasmic reticulum Ca2+ pool (58), or U73122 to inhibit phospholipase C-mediated phosphoinositide breakdown (59) did not affect thrombin-induced tyrosine phosphorylation of focal adhesion proteins in HEK 293 cells (Fig. 2).


View larger version (45K):
[in this window]
[in a new window]
 
Fig. 2.   Thrombin-induced tyrosine phosphorylation is prevented by cytochalasin D but is not inhibited by GF109203X, pertussis toxin, thapsigargin, or U73122. HEK 293 cells were washed and incubated in DMEM before treatment with inhibitors (+) or solvent (-) as indicated. Cells were incubated for 1 h in 3.5 µM GF109203X (GFI), for 2 h in 2 µM cytochalasin D (CytoD), for 2 h in 30 ng/ml pertussis toxin (PTx), for 30 min in 30 nM thapsigargin, and for 1.5 h in 10 µM U73122, as indicated. The cells were then lysed, and tyrosine phosphorylation was analyzed by immunoprecipitation (IP) of the cell lysates with rabbit antiserum directed against p125fak (FAK), mAb directed against paxillin (PAX), or mAb directed against p130cas (CAS) and Western blotting (Blot) the immunoprecipitates with anti-Tyr(P) mAb 4G10 (PY) as indicated. The Western blots of the p125fak immunoprecipitates (FAK) were reblotted with rabbit antiserum directed against p125fak (FAK). The positions of immunoreactive p125fak at apparent Mr 125,000, paxillin at apparent Mr 60,000-70,000, and p130cas at apparent Mr 130,000 are indicated by the arrows to the left of each set of panels.

To determine whether the thrombin-induced increase in the tyrosine phosphorylation of p125fak, paxillin, and p130cas is dependent upon an intact actin cytoskeleton, we tested the effect of cytochalasin D on tyrosine phosphorylation in HEK 293 cells stimulated with thrombin. As shown in Fig. 2 (upper middle panels), cytochalasin D pretreatment inhibited the thrombin-induced tyrosine phosphorylation of p125fak, paxillin, and p130cas in HEK 293 cells, indicating that an intact actin cytoskeleton is required. These results indicate that the signal transduction pathway leading to the tyrosine phophorylation of focal adhesion proteins in HEK 293 cells is very similar to that extensively studied in Swiss 3T3 cells. Thus, HEK 293 cells appear to be an appropriate cellular system to test the effects of mutationally active Galpha 12 and Galpha 13.

Galpha 12QL and Galpha 13QL Induce Tyrosine Phosphorylation of p125fak, Paxillin, and p130cas in HEK 293 Cells-- Mutations in the catalytic domain of Galpha subunits that inhibit their intrinsic GTPase activity are known to convert these proteins into constitutively active alpha  -subunits (60). To examine the effects of Galpha subunits on tyrosine phosphorylation, HEK 293 cells were transiently transfected with expression plasmids encoding the constitutively active Galpha mutants Galpha 12QL, Galpha 13QL, Galpha i-2QL, and Galpha qQL, which are deficient in GTPase activity (37, 49, 50). Given that pertussis toxin does not interfere with agonist-stimulated tyrosine phosphorylation of focal adhesion proteins, Galpha i was tested as a negative control. Conversely, because PKC activation leads to tyrosine phosphorylation of p125fak, paxillin, and p130cas, Galpha q, which stimulates phospholipase C-mediated phosphoinositide hydrolysis and thereby PKC (61-63), was included as a positive control. The extracts of transfected cells were immunoprecipitated with the anti-Tyr(P) mAb PY72, and the immunoprecipitates were analyzed by SDS-polyacrylamide gel electrophoresis and Western blotting with the anti-Tyr(P) mAb 4G10. As illustrated by Fig. 3 (upper panel), HEK 293 cells overexpressing constitutively active mutant Galpha 12QL, Galpha 13QL, or Galpha qQL proteins exhibited increased tyrosine phosphorylation of a set of proteins with apparent Mr of 110,000-130,000, 97,000, and 60,000-70,000. In contrast, transient transfection of HEK 293 cells with activated Galpha i-2QL expression plasmids did not increase tyrosine phosphorylation. Overexpression of wild-type Galpha 12 and Galpha 13 in HEK 293 cells also did not induce tyrosine phosphorylation (data not shown), suggesting that the effects of Galpha 12QL, Galpha 13QL, and Galpha qQL were specific for the activated state of these Galpha subunits rather than due to the modulation of beta gamma subunit availability. No stimulation of protein tyrosine phosphorylation was observed after treatment of HEK 293 cells with medium conditioned by cells transfected transiently with activated Galpha 12QL or Galpha 13QL expression plasmids (data not shown), suggesting that the increased tyrosine phosphorylation was not mediated by secreted factors.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 3.   Galpha 12QL, Galpha 13QL, and Galpha qQL induce tyrosine phosphorylation of p125fak and paxillin in HEK 293 cells. HEK 293 cells were transfected using lipofectAMINE with the following vectors (Galpha ): pcDNA1 without Galpha insert (-) or pcDNA1 encoding constitutively active mutant Galpha 12QL (12*), constitutively active mutant Galpha 13QL (13*), constitutively active mutant Galpha i-2QL (i*), or constitutively active mutant Galpha qQL (q*). Three days after transfection, the cells were washed and incubated for 1 h in DMEM before treatment for 10 min with 1 NIH unit thrombin/ml (+) or solvent (-), and the cells were lysed. Upper Panel, total tyrosine phosphorylation was analyzed by immunoprecipitation (IP) of the cell lysates with anti-Tyr(P) mAb PY72 (PY) and Western blotting (Blot) the immunoprecipitates with anti-Tyr(P) mAb 4G10 (PY). The positions of the migration of the molecular weight markers (in kDa) are indicated to the left. Middle panels, tyrosine phosphorylation of individual proteins was also analyzed by immunoprecipitation (IP) with rabbit antiserum directed against p125fak (FAK) or mAb directed against paxillin (PAX) and Western blotting (Blot) the immunoprecipitates with anti-Tyr(P) mAb 4G10 (PY). The Western blot of the mAb anti-p125fak immunoprecipitates (FAK) was reblotted with rabbit antiserum directed against p125fak (FAK). The positions of immunoreactive p125fak at apparent Mr 125,000 and paxillin at apparent Mr 60,000-70,000 are indicated by the arrows on the left. Lower panels, levels of expression of Galpha subunits were analyzed by Western blotting (Blot) aliquots of total cell lysates with antisera directed against Galpha 12 (alpha 12), Galpha 13 (alpha 13), Galpha i-1/alpha i-2 (alpha i), or Galpha q (alpha q). The positions of immunoreactive Galpha 12 (alpha 12*), Galpha 13 (alpha 13*), Galpha i-2 (alpha iota *), and Galpha q (alpha q*) at apparent Mr 43,000 are indicated by the arrows to the left.

The pattern of increased total tyrosine phosphorylation in response to the constitutively active mutants Galpha 12QL, Galpha 13QL, or Galpha qQL was identical to that induced by treatment of HEK 293 cells with thrombin, LPA, or phorbol 12,13-dibutyrate. As p125fak and paxillin are tyrosine-phosphorylated in response to these stimuli in HEK 293 cells, we investigated whether these same proteins are tyrosine phosphorylated in response to activated Galpha 12, Galpha 13, and Galpha q in HEK 293 cells. As illustrated by Fig. 3 (middle panel), HEK 293 cells transfected with Galpha 12QL, Galpha 13QL, or Galpha qQL subunits exhibited increased tyrosine phosphorylation of p125fak and paxillin. Western blot analysis confirmed that similar amounts of p125fak were immunoprecipitated under all conditions. As shown in Fig. 3 (lower panel), we confirmed that the cells transfected with the Galpha 12QL, Galpha 13QL, Galpha i-2QL, or Galpha qQL expression plasmids were overexpressing these Galpha subunits.

Tyrosine Phosphorylation in Response to Galpha 12QL and Galpha 13QL Requires an Intact Actin Cytoskeleton-- Agonist-stimulated tyrosine phosphorylation of p125fak, paxillin, and p130cas is inhibited by treatment of Swiss 3T3 cells or HEK 293 cells with cytochalasin D, which selectively disrupts the actin cytoskeleton (3, 14, 15, 64). To determine whether the increase in the tyrosine phosphorylation of p125fak and paxillin induced by activated Galpha 12 or Galpha 13 is dependent upon an intact actin cytoskeleton, we tested the effect of cytochalasin D on tyrosine phosphorylation in HEK 293 cells transfected transiently with the Galpha 12QL or Galpha 13QL expression vectors. As shown in Fig. 4 (upper panels), cytochalasin D inhibited the Galpha 12QL- and Galpha 13QL-induced tyrosine phosphorylation of p125fak and paxillin. Western blotting of total cell lysates with antisera to the Galpha subunits demonstrated that cytochalasin D treatment did not alter expression levels of the transfected Galpha subunits (Fig. 4, lower panels). Cytochalasin D also inhibited Galpha qQL- induced tyrosine phosphorylation (data not shown).


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 4.   Galpha 12QL- and Galpha 13QL-induced tyrosine phosphorylation is inhibited by cytochalasin D. HEK 293 cells were transfected using calcium phosphate precipitation with the following vectors (Galpha ): pcDNA1 without Galpha insert (-) or pcDNA1 encoding constitutively active mutant Galpha 12QL (12*) or constitutively active mutant Galpha 13QL (13*). Three days after transfection, the cells were washed and incubated for 2 h in DMEM containing 2 µM cytochalasin D (+) or solvent (-) before lysing the cells. Upper panels, tyrosine phosphorylation was analyzed by immunoprecipitation (IP) of the cell lysates with mAb 2A7 directed against p125fak (FAK) or anti-Tyr(P) mAb 4G10 (PY) and Western blotting (Blot) the immunoprecipitates with anti-Tyr(P) mAb 4G10 (PY). The Western blot of the mAb anti-p125fak immunoprecipitates (FAK) was reprobed with rabbit antiserum directed against p125fak (FAK). The positions of immunoreactive p125fak at apparent Mr 125,000 and paxillin at apparent Mr 60,000-70,000 are indicated by the arrows on the left. Lower panels, levels of expression of Galpha subunits were analyzed by Western blotting (Blot) aliquots of the total cell lysates with antisera directed against Galpha 12 (alpha 12) or Galpha 13 (alpha 13). The positions of immunoreactive Galpha 12 (alpha 12*) and Galpha 13 (alpha 13*) at apparent Mr 43,000 are indicated by the arrows on the left.

alpha 12QL and Galpha 13QL Induce Tyrosine Phosphorylation of p125fak, Paxillin, and p130cas in a Rho-dependent Manner-- The C. botulinum C3 toxin, which specifically ADP-ribosylates RhoA, RhoB, and RhoC, resulting in the functional inhibition of these GTP-binding proteins, can be used to determine whether a cellular response requires functional Rho (65). This approach has been used to demonstrate that in Swiss-3T3 cells, bombesin-, LPA- and toxin-stimulated tyrosine phosphorylation of p125fak, paxillin, and p130cas requires functional Rho (25-27). To determine whether the Galpha 12QL- or Galpha 13QL-induced increases in the tyrosine phosphorylation of p125fak and paxillin are dependent upon Rho, we cotransfected HEK 293 cells with either the Galpha 12QL or the Galpha 13QL expression vector and with a C3 toxin expression vector. We then immunoprecipitated lysates from the transfected cells with the anti-Tyr(P) mAb PY 72, and the immunoprecipitates were analyzed by Western blotting with the anti-Tyr(P) mAb 4G10. As illustrated by Fig. 5 (upper panel), the increase in the tyrosine phosphorylation of proteins with apparent Mr of 110,000-130,000, 97,000, and 60,000-70,000 induced by either Galpha 12QL or Galpha 13QL was inhibited by cotransfection with the C3 toxin expression vector. The Galpha qQL-induced tyrosine phosphorylation of this set of proteins was also inhibited by cotransfection with the C3 toxin expression vector (data not shown). In addition, we immunoprecipitated lysates of cotransfected cells with mAbs directed against p125fak, paxillin, and p130cas and subjected the immunoprecipitates to Western blot analysis with the anti-Tyr(P) mAb 4G10. As shown in Fig. 5 (middle panels), the Galpha 12QL- and Galpha 13QL-induced tyrosine phosphorylation of p125fak, paxillin, and p130cas was inhibited by cotransfection with the C3 toxin expression vector. Western blotting with antisera to the Galpha subunits demonstrated that cotransfection with C3 toxin plasmid did not alter the expression levels of the transfected Galpha subunits (Fig. 5, lower panels).


View larger version (52K):
[in this window]
[in a new window]
 
Fig. 5.   Galpha 12QL- and Galpha 13QL-induced tyrosine phosphorylation of p125fak, paxillin, and p130cas is blocked by the Rho-inhibitor C3 toxin. HEK 293 cells were cotransfected with Galpha and C3 expression vectors using lipofectAMINE as indicated. The cells were transfected with empty pcDNA1 vectors (-) or pcDNA1 encoding constitutively active mutants Galpha 12QL (12*) or Galpha 13QL (13*) in combination with the C3 vector (C3 +). Three days after transfection, the cells were washed and incubated for 2 h in DMEM before being lysed. The protein concentration in each of the lysates was adjusted to 1 mg protein/ml. Upper panel, total tyrosine phosphorylation was analyzed by immunoprecipitation (IP) of the cell lysates with anti-Tyr(P) mAb PY72 (PY) and Western blotting (Blot) the immunoprecipitates with anti-Tyr(P) mAb 4G10 (PY). The positions of the migration of the molecular mass markers (in kDa) are indicated to the left. Middle panels, tyrosine phosphorylation of individual proteins was also analyzed by immunoprecipitation (IP) with mAb 2A7 directed against p125fak (FAK), mAb directed against paxillin (PAX), or mAb directed against p130cas (CAS) and Western blotting (Blot) the immunoprecipitates with anti-Tyr(P) mAb 4G10 (PY). The Western blot of the mAb anti-p125fak immunoprecipitates (FAK) was reblotted with rabbit antiserum directed against p125fak (FAK). The positions of immunoreactive p125fak at apparent Mr 125,000, paxillin at apparent Mr 60,000-70,000, and p130cas at apparent Mr 130,000 are indicated by the arrows on the left. Lower panels, levels of expression of Galpha subunits were analyzed by Western blotting (Blot) aliquots of total cell lysates with antisera directed against Galpha 12 (alpha 12) or Galpha 13 (alpha 13). The positions of immunoreactive Galpha 12 (alpha 12*) and Galpha 13 (alpha 13*) at apparent Mr 43,000 are indicated by the arrows to the left.

We verified that thrombin-induced tyrosine phosphorylation of the focal adhesion proteins p125fak, paxillin, and p130cas in HEK 293 cells was also inhibited by transfection with the C3 toxin expression vector. In contrast, epidermal growth factor-induced tyrosine phosphorylation of a protein of apparent Mr 170,000 (presumably the epidermal growth factor receptor) was not inhibited by transfection of HEK 293 cells with the expression plasmid encoding C3 toxin, indicating that this toxin inhibited tyrosine phosphorylation of focal adhesion proteins in a selective manner (results not shown).

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Activation of GPCRs for mitogenic neuropeptides and bioactive lipids leads to a pertussis toxin-insensitive tyrosine phosphorylation of multiple protein substrates including the nonreceptor tyrosine kinase p125fak and the adaptor proteins paxillin and p130cas. The mechanism(s) linking activation of GPCRs to increases in protein tyrosine phosphorylation remains poorly understood. In the present study, we have used transient transfection of HEK 293 cells with expression plasmids encoding constitutively active Galpha 12 and Galpha 13 to investigate the involvement of the G12 subfamily of Galpha proteins in tyrosine phosphorylation of the nonreceptor tyrosine kinase p125fak and of the adaptor proteins paxillin and p130cas. We report for the first time that HEK 293 cells expressing constitutively active Galpha 12 and Galpha 13 mutants exhibit increased tyrosine phosphorylation of p125fak, paxillin, and p130cas. Identical increases in tyrosine phosphorylation of these focal adhesion proteins were observed in HEK 293 cells treated with thrombin. This is noteworthy with reference to the previous reports that thrombin receptors couple to Galpha 12 and Galpha 13 in platelets and to Galpha 12 in astrocytoma cells (43, 55) and, in particular, that fibroblasts lacking Galpha 13 exhibit a greatly diminished migratory response to thrombin (44). Our observations reveal a novel connection between activated Galpha 12 and Galpha 13 and increases in tyrosine phosphorylation of p125fak, paxillin, and p130cas.

The signal transduction mechanism that mediates Galpha 12- and Galpha 13-induced increases in tyrosine phosphorylation of p125fak, paxillin, and p130cas in HEK 293 cells has several features in common with the mechanism extensively studied in Swiss 3T3 cells mediating tyrosine phosphorylation of these proteins in response to LPA and bombesin, which signal by activation of GPCRs. The common features in the signal transduction pathway leading to tyrosine phosphorylation of p125fak, paxillin, and p130cas include a requirement for an intact actin cytoskeleton, as indicated by the block of the tyrosine phosphorylation response by treatment with cytochalasin D, which specifically disrupts the actin cytoskeleton (3, 4, 14, 15, 20, 64). Another common feature is the requirement for functional Rho, as indicated by inhibition with the C. botulinum C3 toxin, which ADP-ribosylates and functionally inactivates Rho (25, 26, 66). These observations suggest that Galpha 12 and Galpha 13 may couple GPCRs to increases in tyrosine phosphorylation of p125fak, paxillin, and p130cas.

It has been proposed that the mitogen-induced increases in tyrosine phosphorylation of p125fak, paxillin, and p130cas are downstream of Rho activation, stress fiber formation, and focal adhesion assembly (4, 25-28, 67, 68). Activated Galpha 12 and Galpha 13 have been shown to induce Rho activation (69) and Rho-dependent biological responses, including stress fiber formation and focal adhesion assembly (42, 70, 71). These results suggest that these G-proteins may couple GPCRs to the activation of Rho. Our observation that activated Galpha 12 and Galpha 13 mediate a Rho-dependent increase in tyrosine phosphorylation of p125fak, paxillin, and p130cas further supports the hypothesis that Galpha 12 and Galpha 13, which together comprise the G12 subfamily of Galpha proteins, couple the activation of GPCRs to the activation of Rho. Taken together, these findings suggest the existence of a signal transduction pathway whereby ligand occupation of GPCRs activates Galpha 12 and/or Galpha 13, which subsequently activate Rho, presumably by a mechanism involving recruitment and activation of a GDP/GTP exchange factor. Activated Rho would induce the formation of actin stress fibers and promote the assembly of focal adhesions, resulting in recruitment of p125fak to focal adhesions and tyrosine phosphorylation of p125fak, paxillin, and p130cas. This hypothesis warrants further experimental work.

Direct activation of PKC also leads to tyrosine phosphorylation of focal adhesion proteins in either Swiss 3T3 cells (14, 15, 20) or in HEK 293 cells (Fig. 2). Accordingly, we found that HEK 293 cells expressing constitutive active Galpha q, which couples to phospholipase C and PKC (61-63), exhibit increased tyrosine phosphorylation of focal adhesion proteins, which was dependent upon an intact cytoskeleton and functional Rho. In light of the report that, in contrast to Galpha 12 and Galpha 13, Galpha q does not induce stress fiber formation and focal adhesions in Swiss 3T3 cells (42), Galpha q has not been thought to couple GPCRs to the activation of Rho. However, a recent report has suggested that GPCRs can induce the phosphorylation of Tiam1, a Rac-1-specific exchange factor, in a manner that is dependent upon PKC and independent of pertussis toxin-sensitive G-proteins (72). In Swiss 3T3 cells, Cdc42, Rac, and Rho have been placed in a hierarchical cascade wherein Cdc42 activates Rac, which in turn activates Rho (73). Therefore, Galpha q may induce the Rho-dependent tyrosine phosphorylation of focal adhesion proteins via an activation of Rac, which may subsequently activate Rho. Because agonist-mediated tyrosine phosphorylation of focal adhesion proteins occurs independently of PKC, the precise physiological significance of the PKC-dependent pathway is unclear.

There is increasing evidence indicating that Galpha 12 and Galpha 13 are involved in cell migration, proliferation, and transformation (36, 38-40, 43, 44, 48). Downstream targets through which Galpha 12 and Galpha 13 act may include Ras-, Rac-, Rho-, and Cdc42-dependent pathways leading to cytoskeletal reorganization and to the activation of mitogen-activated protein kinase, Jun N-terminal kinase, the Na+-H+ exchanger, and the c-fos serum response element (40-42, 46-48). In this context, our results revealing that activated Galpha 12 and Galpha 13 induce increases in the level of tyrosine phosphorylation of p125fak, paxillin, and p130cas suggest novel mechanisms of action of these Galpha subunits. These findings assume an added importance in view of increasing evidence implicating p125fak and p130cas in cell migration, proliferation, and transformation. Gene disruption experiments have demonstrated a critical role of p125fak in embryonic development, cell migration, and turnover of focal adhesions (29, 74), and microinjection of dominant negative fragments of p125fak prevented serum stimulation of DNA synthesis (75). The adaptor protein p130cas has also been implicated in agonist-stimulated mitogenesis and in cell transformation (12, 20, 76) and has recently been identified as a mediator of p125fak-mediated cell migration (31). Interestingly, embryonic fibroblasts lacking Galpha 13 also display a greatly impaired migratory response to thrombin receptor activation (44). Taken together with the results presented here, these findings raise the attractive possibility that p125fak and p130cas are downstream targets of Galpha 13 in a signal transduction pathway that regulates cell migration in response to GPCR agonists. Future studies should assess the contribution of increased tyrosine phosphorylation of p125fak, paxillin, and p130cas to the growth promoting and transforming activities of Galpha 12 and Galpha 13.

    ACKNOWLEDGEMENTS

We thank Dr. Henry R. Bourne for the kind gifts of the expression constructs for Galpha 12-Q229L and Galpha 13-Q226L and Dr. Richard Treisman for the kind gifts of the expression constructs for C3 and beta -galactosidase. We also thank Dr. Thomas Seufferlein for advice on transfection protocols and Dr. Ray Harris of Life Technologies, Inc. for sharing information on conditions for transfecting HEK 293 cells with LipofectAMINETM.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: Dept. of Biochemistry, School of Medicine, University of North Carolina, Chapel Hill, NC 27599-7260.

§ To whom correspondence should be addressed: 900 Veteran Ave., Warren Hall Room 11-124, Dept. of Medicine, School of Medicine, UCLA, Los Angeles, CA 90095-1786. Tel.: 310-794-6610; Fax: 310-267-2399.

1 The abbreviations used are: LPA, lysophosphatidic acid; anti-Tyr(P), anti-phosphotyrosine; C3 toxin, C. botulinum C3 exoenzyme; DMEM, Dulbecco's modified Eagle's medium; Galpha 12QL, Galpha 13QL, Galpha i-2QL, and Galpha qQL, constitutively active mutant Galpha 12-Q229L, Galpha 13-Q226L, Galpha i-2-Q205L, and Galpha q-Q209L subunits, respectively; G-protein, guanine nucleotide regulatory protein; GPCR, G-protein-coupled receptors; mAb, monoclonal antibody; p125fak, p125 focal adhesion kinase; p130cas, p130 Crk-associated substrate; PKC, protein kinase C; PIPES, piperazine-N,N'-bis(2-ethanesulfonic acid) ; EF, elongation factor.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Rozengurt, E. (1995) Cancer Surv. 24, 81-96[Medline] [Order article via Infotrieve]
  2. Seufferlein, T., and Rozengurt, E. (1994) J. Biol. Chem. 269, 27610-27617[Abstract/Free Full Text]
  3. Seufferlein, T., and Rozengurt, E. (1994) J. Biol. Chem. 269, 9345-9351[Abstract/Free Full Text]
  4. Seufferlein, T., and Rozengurt, E. (1995) J. Biol. Chem. 270, 24343-24351[Abstract/Free Full Text]
  5. Zachary, I., Sinnett-Smith, J., and Rozengurt, E. (1991) J. Biol. Chem. 266, 24126-24133[Abstract/Free Full Text]
  6. Zachary, I., Gil, J., Lehmann, W., Sinnett-Smith, J., and Rozengurt, E. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4577-4581[Abstract]
  7. Leeb-Lundberg, L. M., and Song, X. H. (1991) J. Biol. Chem. 266, 7746-7749[Abstract/Free Full Text]
  8. Schaller, M. D., Borgman, C. A., Cobb, B. S., Vines, R. R., Reynolds, A. B., and Parsons, J. T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5192-5196[Abstract]
  9. Hanks, S. K., Calalb, M. B., Harper, M. C., and Patel, S. K. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 8487-8491[Abstract]
  10. Salgia, R., Li, J. L., Lo, S. H., Brunkhorst, B., Kansas, G. S., Sobhany, E. S., Sun, Y., Pisick, E., Hallek, M., Ernst, T., Tanravahi, R., Chen, L. B., and Griffin, J. D. (1995) J. Biol. Chem. 270, 5039-5047[Abstract/Free Full Text]
  11. Turner, C. E., and Miller, J. T. (1994) J. Cell Sci. 107, 1583-1591[Abstract/Free Full Text]
  12. Sakai, R., Iwamatsu, A., Hirano, N., Ogawa, S., Tanaka, T., Mano, H., Yazaki, Y., and Hirai, H. (1994) EMBO J. 13, 3748-3756[Abstract]
  13. Zachary, I., Sinnett-Smith, J., and Rozengurt, E. (1992) J. Biol. Chem. 267, 19031-19034[Abstract/Free Full Text]
  14. Zachary, I., Sinnett-Smith, J., Turner, C. E., and Rozengurt, E. (1993) J. Biol. Chem. 268, 22060-22065[Abstract/Free Full Text]
  15. Sinnett-Smith, J., Zachary, I., Valverde, A. M., and Rozengurt, E. (1993) J. Biol. Chem. 268, 14261-14268[Abstract/Free Full Text]
  16. Seufferlein, T., Withers, D. J., Broad, S., Herget, T., Walsh, J. H., and Rozengurt, E. (1995) Cell Growth Differ. 6, 383-393[Abstract]
  17. Lach, E. B., Broad, S., and Rozengurt, E. (1995) Cell Growth Differ. 6, 1427-1435[Abstract]
  18. Leeb-Lundberg, L. M., Song, X. H., and Mathis, S. A. (1994) J. Biol. Chem. 269, 24328-24334[Abstract/Free Full Text]
  19. Charlesworth, A., Broad, S., and Rozengurt, E. (1996) Oncogene 12, 1337-1345[Medline] [Order article via Infotrieve]
  20. Casamassima, A., and Rozengurt, E. (1997) J. Biol. Chem. 272, 9363-9370[Abstract/Free Full Text]
  21. Ridley, A. J., and Hall, A. (1992) Cell 70, 389-399[Medline] [Order article via Infotrieve]
  22. Rankin, S., and Rozengurt, E. (1994) J. Biol. Chem. 269, 704-710[Abstract/Free Full Text]
  23. Hall, A. (1994) Annu. Rev. Cell Biol. 10, 31-54[CrossRef]
  24. Narumiya, S., Ishizaki, T., and Watanabe, N. (1997) FEBS Lett. 410, 68-72[CrossRef][Medline] [Order article via Infotrieve]
  25. Rankin, S., Morii, N., Narumiya, S., and Rozengurt, E. (1994) FEBS Lett. 354, 315-319[CrossRef][Medline] [Order article via Infotrieve]
  26. Seckl, M. J., Morii, N., Narumiya, S., and Rozengurt, E. (1995) J. Biol. Chem. 270, 6984-6990[Abstract/Free Full Text]
  27. Lacerda, H. M., Lax, A. J., and Rozengurt, E. (1996) J. Biol. Chem. 271, 439-445[Abstract/Free Full Text]
  28. Lacerda, H. M., Pullinger, G. D., Lax, A. J., and Rozengurt, E. (1997) J. Biol. Chem. 272, 9587-9596[Abstract/Free Full Text]
  29. Ilic, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., and Yamamoto, T. (1995) Nature 377, 539-544[CrossRef][Medline] [Order article via Infotrieve]
  30. Cary, L. A., Chang, J. F., and Guan, J. L. (1996) J. Cell Sci. 109, 1787-1794[Abstract/Free Full Text]
  31. Cary, L. A., Han, D. C., Polte, T. R., Hanks, S. K., and Guan, J. L. (1998) J. Cell Biol. 140, 211-221[Abstract/Free Full Text]
  32. Richardson, A., Malik, R. K., Hildebrand, J. D., and Parsons, J. T. (1997) Mol. Cell. Biol. 17, 6906-6914[Abstract]
  33. Moolenaar, W. H., Kranenburg, O., Postma, F. R., and Zondag, G. C. (1997) Curr. Opin. Cell Biol. 9, 168-173[CrossRef][Medline] [Order article via Infotrieve]
  34. Strathmann, M. P., and Simon, M. I. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 5582-5586[Abstract]
  35. Spicher, K., Kalkbrenner, F., Zobel, A., Harhammer, R., Nürnberg, B., Söling, A., and Schultz, G. (1994) Biochem. Biophys. Res. Commun. 198, 906-914[CrossRef][Medline] [Order article via Infotrieve]
  36. Jiang, H., Wu, D., and Simon, M. I. (1993) FEBS Lett. 330, 319-322[CrossRef][Medline] [Order article via Infotrieve]
  37. Voyno-Yasenetskaya, T. A., Pace, A. M., and Bourne, H. R. (1994) Oncogene 9, 2559-2565[Medline] [Order article via Infotrieve]
  38. Chan, A. M., Fleming, T. P., McGovern, E. S., Chedid, M., Miki, T., and Aaronson, S. A. (1993) Mol. Cell. Biol. 13, 762-768[Abstract]
  39. Xu, N., Voyno-Yasenetskaya, T., and Gutkind, J. S. (1994) Biochem. Biophys. Res. Commun. 201, 603-609[CrossRef][Medline] [Order article via Infotrieve]
  40. Mitsui, H., Takuwa, N., Kurokawa, K., Exton, J. H., and Takuwa, Y. (1997) J. Biol. Chem. 272, 4904-4910[Abstract/Free Full Text]
  41. Collins, L. R., Ricketts, W. A., Olefsky, J. M., and Brown, J. H. (1997) Oncogene 15, 595-600[CrossRef][Medline] [Order article via Infotrieve]
  42. Buhl, A. M., Johnson, N. L., Dhanasekaran, N., and Johnson, G. L. (1995) J. Biol. Chem. 270, 24631-24634[Abstract/Free Full Text]
  43. Aragay, A. M., Collins, L. R., Post, G. R., Watson, A. J., Feramisco, J. R., Brown, J. H., and Simon, M. I. (1995) J. Biol. Chem. 270, 20073-20077[Abstract/Free Full Text]
  44. Offermanns, S., Mancino, V., Revel, J. P., and Simon, M. I. (1997) Science 275, 533-536[Abstract/Free Full Text]
  45. Collins, L. R., Minden, A., Karin, M., and Brown, J. H. (1996) J. Biol. Chem. 271, 17349-17353[Abstract/Free Full Text]
  46. Hooley, R., Yu, C. Y., Symons, M., and Barber, D. L. (1996) J. Biol. Chem. 271, 6152-6158[Abstract/Free Full Text]
  47. Lin, X., Voyno-Yasenetskaya, T. A., Hooley, R., Lin, C. Y., Orlowski, J., and Barber, D. L. (1996) J. Biol. Chem. 271, 22604-22610[Abstract/Free Full Text]
  48. Fromm, C., Coso, O. A., Montaner, S., Xu, N., and Gutkind, J. S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 10098-10103[Abstract/Free Full Text]
  49. Wong, Y. H., Federman, A., Pace, A. M., Zachary, I., Evans, T., Pouysségur, J., and Bourne, H. R. (1991) Nature 351, 63-65[CrossRef][Medline] [Order article via Infotrieve]
  50. Wedegaertner, P. B., Chu, D. H., Wilson, P. T., Levis, M. J., and Bourne, H. R. (1993) J. Biol. Chem. 268, 25001-25008[Abstract/Free Full Text]
  51. Hill, C. S., and Treisman, R. (1995) EMBO J. 14, 5037-5047[Abstract]
  52. Wilson, S. P., Liu, F., Wilson, R. E., and Housley, P. R. (1995) Anal. Biochem. 226, 212-220[CrossRef][Medline] [Order article via Infotrieve]
  53. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  54. Haycock, J. W. (1993) Anal. Biochem. 208, 397-399[CrossRef][Medline] [Order article via Infotrieve]
  55. Offermanns, S., Laugwitz, K. L., Spicher, K., and Schultz, G. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 504-508[Abstract]
  56. Toullec, D., Pianetti, P., Coste, H., Bellevergue, P., Grand-Perret, T., Ajakane, M., Baudet, V., Boissin, P., Boursier, E., Loriolle, F., Duhamel, L., Charon, D., and Kirilovsky, J. (1991) J. Biol. Chem. 266, 15771-15781[Abstract/Free Full Text]
  57. Yeo, E. J., and Exton, J. H. (1995) J. Biol. Chem. 270, 3980-3988[Abstract/Free Full Text]
  58. Thastrup, O., Cullen, P. J., Drøbak, B. K., Hanley, M. R., and Dawson, A. P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 2466-2470[Abstract]
  59. Yule, D. I., and Williams, J. A. (1992) J. Biol. Chem. 267, 13830-13835[Abstract/Free Full Text]
  60. Bourne, H. R., Sanders, D. A., and McCormick, F. (1991) Nature 349, 117-127[CrossRef][Medline] [Order article via Infotrieve]
  61. Wu, D. Q., Lee, C. H., Rhee, S. G., and Simon, M. I. (1992) J. Biol. Chem. 267, 1811-1817[Abstract/Free Full Text]
  62. Berstein, G., Blank, J. L., Smrcka, A. V., Higashijima, T., Sternweis, P. C., Exton, J. H., and Ross, E. M. (1992) J. Biol. Chem. 267, 8081-8088[Abstract/Free Full Text]
  63. Exton, J. H. (1996) Annu. Rev. Pharmacol. Toxicol. 36, 481-509[CrossRef][Medline] [Order article via Infotrieve]
  64. Seufferlein, T., Withers, D. J., Mann, D., and Rozengurt, E. (1996) Mol. Biol. Cell 7, 1865-1875[Abstract]
  65. Aktories, K. (1997) J. Clin. Invest. 99, 827-829[Free Full Text]
  66. Kumagai, N., Morii, N., Fujisawa, K., Nemoto, Y., and Narumiya, S. (1993) J. Biol. Chem. 268, 24535-24538[Abstract/Free Full Text]
  67. Kumagai, N., Morii, N., Fujisawa, K., Yoshimasa, T., Nakao, K., and Narumiya, S. (1993) FEBS Lett. 329, 273-276[CrossRef][Medline] [Order article via Infotrieve]
  68. Flinn, H. M., and Ridley, A. J. (1996) J. Cell Sci. 109, 1133-1141[Abstract/Free Full Text]
  69. Gohla, A., Harhammer, R., and Schultz, G. (1998) J. Biol. Chem. 273, 4653-4659[Abstract/Free Full Text]
  70. Althoefer, H., Eversole-Cire, P., and Simon, M. I. (1997) J. Biol. Chem. 272, 24380-24386[Abstract/Free Full Text]
  71. Plonk, S. G., Park, S. K., and Exton, J. H. (1998) J. Biol. Chem. 273, 4823-4826[Abstract/Free Full Text]
  72. Fleming, I. N., Elliot, C. M., Collard, J. G., and Exton, J. H. (1997) J. Biol. Chem. 272, 33105-33110[Abstract/Free Full Text]
  73. Nobes, C. D., and Hall, A. (1995) Cell 81, 53-62[Medline] [Order article via Infotrieve]
  74. Ilic, D., Damsky, C. H., and Yamamoto, T. (1997) J. Cell Sci. 110, 401-407[Abstract/Free Full Text]
  75. Gilmore, A. P., and Romer, L. H. (1996) Mol. Biol. Cell 7, 1209-1224[Abstract]
  76. Auvinen, M., Paasinen-Sohns, A., Hirai, H., Andersson, L. C., and Hölttä, E. (1995) Mol. Cell. Biol. 15, 6513-6525[Abstract]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.